News
World Kidney Cancer Q&A Day – June 21st
As members of the International Kidney Cancer Coalition (IKCC), KCCure is a proud partner and participant of the second-annual World Kidney Cancer Q&A Day.
Report from ASCO – CARMENA Trial
KCCure recently attended ASCO - the world's largest cancer research conference. Learn more below on why everyone in the kidney cancer world is talking about CARMENA.
Help Share the Patient Perspective at ASCO
During ASCO, new data was presented from the “CARMENA” trial showing that overall survival for metastatic patients was not improved by performing a nephrectomy (or removing the primary tumor). This is a controversial question and one that is being debated by many physicians. We want to include the patient voice in that debate. Please take a few minutes to fill out this brief survey to help us sharing the patient perspective at ASCO. As always, your personal data will not be sharing with anyone. Thank you for taking part!
KCCure Represents Patients at AUA 2018
For the second year in a row, KCCure represented kidney cancer patients at the annual meeting for the American Urological Association. This year, KCCure was instrumental in planning for the meeting by serving on the AUA Steering Committee for Patient Advocacy Efforts.
KCCure President Dena Battle elected to NCI Genitourinary Steering Committee (GUSC)
Kidney Cancer Research Alliance (KCCure) President Dena Battle has been elected to represent patients on the National Cancer Institute's Genitourinary Steering Committee(GUSC). The primary focus of the committee is to address design prioritization and evaluation of concepts for phase 2 and 3 clinical trials in GU cancers. Her term is effective May 25, 2018 and will last through May 2021.
KCCURE HAILS FDA APPROVAL OF FIRST COMBINATION IMMUNOTHERAPY FOR FIRST LINE RENAL CELL CARCINOMA
“Today’s decision by the FDA is a game-changer for patients and physicians managing advanced kidney cancer,” said Hans Hammers M.D., Ph.D., KCCure co-founder and senior co-author of the clinical study for the combination.
KCCure Joins with Partner Organizations for Increased Research Funding
KCCure joined with twelve other kidney cancer advocacy organizations urging Congress to double kidney cancer research funding for the Kidney Cancer Research Program (KCRP) administered by the Congressionally Directed Medical Research Program (CDMRP).
Spotlight on Chromophobe RCC – Interview with Lisa Henske
Today's Voice of Kidney Cancer is Dr. Elizabeth (Lisa) Henske, who runs the Henske Lab at Brigham and Women's Hospital and Harvard Medical School in Boston. One of her principal areas of research is chromophobe renal cell carcinoma (chRCC). She's also one of the newest members of the KCCure scientific advisory board. We're grateful to Dr. Henske for donating her time to answer a few questions about her work in chRCC.
Kidney Cancer Awareness Month
Each day in March, visit us at KCCure, where we’ll share a new story from someone whose life has been touched by kidney cancer. We share Kidney Cancer Patient Stories to let others know that they're not alone.
Kidney Cancer news from ASCO-GU
The 2018 Genitourinary (GU) Cancers Symposium is a three-day scientific and educational meeting focusing on research and clinical applications in GU cancers (which includes kidney, prostate and bladder). For the second year in a row, KCCure participated in this important kidney cancer conference.
March is Kidney Cancer Awareness Month – Share your Story
At KCCure, Kidney Cancer Awareness month is about bringing patients, caregivers, researchers and doctors together to make our collective voice loud and clear. Help us tell the world that this disease exists, that we're fighting and that we need a cure!
KCCure Launches National Kidney Cancer Patient Advisory Board
The Kidney Cancer Research Alliance (KCCure) announced today the formation of a national kidney cancer Patient Advisory Board; a non-voting body made up of patients, caregivers and leaders in the cancer community. The board will be led by patient advocates Michael B. Lawing and Debra Gottsleben.